2396. Fosfomycin Resistance Among Carbapenem-Resistant Enterobacteriaceae Clinical Isolates in Connecticut, 2017
Snayd M, Leung V, Maloney M, Durante A, Macierowski B, Noel D, Muyombwe A, Razeq J, Banach D. 2396. Fosfomycin Resistance Among Carbapenem-Resistant Enterobacteriaceae Clinical Isolates in Connecticut, 2017. Open Forum Infectious Diseases 2018, 5: s714-s715. PMCID: PMC6253430, DOI: 10.1093/ofid/ofy210.2049.Peer-Reviewed Original ResearchState public health laboratoriesCRE isolatesNonsusceptible isolatesFosfomycin resistanceAntimicrobial Susceptibility Testing (EUCAST) criteriaCarbapenem-resistant Enterobacteriaceae infectionsOlder patient ageLimited treatment optionsResistance risk factorsSubstantial proportionEnterobacteriaceae clinical isolatesFosfomycin resistance ratePublic health laboratoriesLaboratory Standards InstituteSusceptibility testing criteriaCRE patientsPatient ageEnterobacteriaceae infectionsTreatment optionsRisk factorsResistance ratesWarrants evaluationCarbapenem resistanceBlaKPC geneCLSI criteria2411. Expanded Susceptibility and Resistance Mechanism Testing Among Carbapenem-Resistant Enterobacteriaceae in Connecticut, 2017
Durante A, Maloney M, Leung V, Macierowski B, Noel D, Razeq J, Banach D. 2411. Expanded Susceptibility and Resistance Mechanism Testing Among Carbapenem-Resistant Enterobacteriaceae in Connecticut, 2017. Open Forum Infectious Diseases 2018, 5: s721-s721. PMCID: PMC6253689, DOI: 10.1093/ofid/ofy210.2064.Peer-Reviewed Original ResearchState public health laboratoriesLaboratory Standards Institute breakpointsPolymerase chain reaction testingReal-time polymerase chain reaction testingCeftazidime/avibactamCarbapenem-resistant EnterobacteriaceaePublic health laboratoriesCRE isolatesEmpiric treatmentCP-CRECarbapenemase testingReaction testingHealth laboratoriesCarbapenemase productionCarbapenem inactivation methodSusceptibility testingCommon carbapenemasesBroth microdilutionNon-CPDisk diffusionInactivation methodCreAntibiogramClinicalAvibactam